{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:19:09Z","timestamp":1792653549138,"version":"4.5.0"},"reference-count":58,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Cryptococcal infections burden the immunocompromised population with unacceptably high morbidity and mortality. This population includes HIV-infected individuals and those undergoing organ transplants, as well as seemingly immunocompetent patients (non-HIV, non-transplant). These groups are difficult to manage with the current therapeutic options and strategies, particularly in resource-limited settings. New trials aimed at providing the best treatment strategies for resource-limited countries that will reduce costs and adverse reactions have focused on decreasing the length of therapy and using more readily accessible antifungal agents such as fluconazole. Furthermore, the emergence of antifungal resistance poses another challenge for successful treatment and may require the development of new agents for improved management. This review will discuss the principles of management, current and future antifungal agents, as well as emerging techniques and future directions of care for this deadly infection.<\/jats:p>","DOI":"10.3390\/jof4030079","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T11:12:58Z","timestamp":1530616378000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Present and Future Therapy of Cryptococcus Infections"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-597X","authenticated-orcid":false,"given":"Ahmad","family":"Mourad","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"George, I.A., Spec, A., Powderly, W.G., and Santos, C.A.Q. (2017). Comparative Epidemiology and Outcomes of HIV, Non-HIV Non-Transplant and Organ Transplant Associated Cryptococcosis: A Population-Based Study. Clin. Infect. Dis.","DOI":"10.1093\/cid\/cix867"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","unstructured":"Molloy, S., Kanyama, C., Heyderman, R., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., and Lesikari, S. (2017). A Randomized Controlled Trial for the Treatment of HIV-Associated Cryptococcal Meningitis in Africa: Oral Fluconazole Plus Flucytosine or One Week Amphotericin-Based Therapy vs. Two Weeks Amphotericin-Based Therapy."},{"key":"ref_5","unstructured":"Jarvis, J.N., Leeme, T.B., Chofle, A.A., Bidwell, G., Molefi, M., Tsholo, K., Lekwape, N., Muthoga, C., Molloy, S., and Harrison, T.S. (2017, January 13\u201316). AMBITION-CM: High-Dose Liposomal Amphotericin For Hiv-Related Cryptococcal Meningitis. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity","volume":"43","author":"Luber","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lestner, J., McEntee, L., Johnson, A., Livermore, J., Whalley, S., Schwartz, J., Perfect, J.R., Harrison, T., and Hope, W. (2017). Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00090-17"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1086\/599112","article-title":"A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gaskell, K.M., Rothe, C., Gnanadurai, R., Goodson, P., Jassi, C., Heyderman, R.S., Allain, T.J., Harrison, T.S., Lalloo, D.G., and Sloan, D.J. (2014). A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110285"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw151","article-title":"Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis","volume":"62","author":"Merry","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/cid\/ciw153","article-title":"Editorial Commentary: Life-saving Antimicrobial Drugs: What Are We Doing to Pricing and Availability?","volume":"62","author":"Perfect","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/ciu937","article-title":"Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986\u20132012","volume":"60","author":"McKenney","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/655143","article-title":"Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count \u2264100 cells\/\u00b5L who start HIV therapy in resource-limited settings","volume":"51","author":"Meya","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/cid\/cix613","article-title":"Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)\u2013Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program","volume":"65","author":"Beyene","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-199202000-00007","article-title":"Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis","volume":"6","author":"Portegies","year":"1992","journal-title":"AIDS"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3109\/23744235.2015.1044260","article-title":"Voriconazole: A novel treatment option for cryptococcal meningitis","volume":"47","author":"Yao","year":"2015","journal-title":"Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa1509024","article-title":"Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis","volume":"374","author":"Beardsley","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/313603","article-title":"Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups","volume":"30","author":"Graybill","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/cid\/ciu596","article-title":"The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis","volume":"59","author":"Rolfes","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/QAI.0000000000000147","article-title":"Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: An operational research study","volume":"66","author":"Meda","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4081\/idr.2015.6173","article-title":"Reversible Deafness and Blindness in a Patient with Cryptococcal Meningitis in Tanzania","volume":"7","author":"Bechamp","year":"2015","journal-title":"Infect. Dis. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mmcr.2017.11.004","article-title":"Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis","volume":"19","author":"Mpoza","year":"2018","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1086\/317614","article-title":"The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans","volume":"182","author":"Feldmesser","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1093\/ofid\/ofx163.1225","article-title":"Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis","volume":"4","author":"Schell","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Shaw, K.J., Schell, W.A., Covel, J., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, O., Tross, M., Webb, P., and Perfect, J.R. (2018). In vitro and in vivo evaluation of APX001a\/APX001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00523-18"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1128\/AAC.01061-16","article-title":"The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis","volume":"60","author":"Koselny","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/jac\/dkx020","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: An emerging fungal pathogen","volume":"72","author":"Nishikawa","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","first-page":"453","article-title":"Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs","volume":"55","author":"Nielsen","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkx410","article-title":"Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lazzarini, C., Haranahalli, K., Rieger, R., Ananthula, H.K., Desai, P.B., Ashbaugh, A., Linke, M.J., Cushion, M.T., Ruzsicska, B., and Haley, J. (2018). Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.00156-18"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/ml300173e","article-title":"Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin h","volume":"3","author":"Singh","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1016\/j.bmcl.2014.07.064","article-title":"Scaffold hopping of sampangine: Discovery of potent antifungal lead compound against Aspergillus fumigatus and Cryptococcus neoformans","volume":"24","author":"Jiang","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/mmy\/myv109","article-title":"Activity of sertraline against Cryptococcus neoformans: In vitro and in vivo assays","volume":"54","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: An open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.00990-07","article-title":"Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis","volume":"52","author":"Kontoyiannis","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00765-13","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Chatterjee, S., and Tatu, U. (2017). Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005836"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1139\/w2012-075","article-title":"Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans","volume":"58","author":"Sidrim","year":"2012","journal-title":"Can. J. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.174.3.1746","article-title":"IFN-\u03b3 at the site of infection determines rate of clearance of infection in cryptococcal meningitis","volume":"174","author":"Siddiqui","year":"2005","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant interferon-\u03b3 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis","volume":"189","author":"Pappas","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1084\/jem.181.1.405","article-title":"Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell","volume":"181","author":"Mukherjee","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1128\/AAC.42.6.1437","article-title":"Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies","volume":"42","author":"Casadevall","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/IAI.00278-07","article-title":"An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo","volume":"75","author":"Rachini","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1369-5274(00)00103-X","article-title":"Melanin and virulence in Cryptococcus neoformans","volume":"3","author":"Casadevall","year":"2000","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1128\/IAI.69.5.3410-3412.2001","article-title":"Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection","volume":"69","author":"Rosas","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/654813","article-title":"Radioimmunotherapy is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection","volume":"202","author":"Bryan","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2217\/fmb.13.79","article-title":"Radioimmunotherapy of Cryptococcus neoformans spares bystander mammalian cells","volume":"8","author":"Bryan","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/iai.59.10.3700-3707.1991","article-title":"Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: Synthesis, characterization, and immunogenicity","volume":"59","author":"Devi","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00130-08","article-title":"Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan","volume":"15","author":"Datta","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Specht, C.A., Lee, C.K., Huang, H., Hester, M.M., Liu, J., Luckie, B.A., Torres Santana, M.A., Mirza, Z., Khoshkenar, P., and Abraham, A. (2017). Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. mBio, 8.","DOI":"10.1128\/mBio.01872-17"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.00274-06","article-title":"Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain","volume":"75","author":"Wormley","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1093\/ofid\/ofx163.1236","article-title":"In Vitro Characterization of the Neurapheresis\u2122 System for the Treatment of Cryptococcal Meningitis","volume":"4","author":"Charalambous","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Smilnak, G., Bartuska, A., Ejikeme, T., Ballard, C., Giamberardino, C., Pagadala, P., Bartuska, A.P., Ejikeme, T.U., Sheng, H., and Verbick, L.Z. (2018). Novel Treatment of Cryptococcal Meningitis via Neuraphresis Filtration. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiy286"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:11:05Z","timestamp":1760195465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["jof4030079"],"URL":"https:\/\/doi.org\/10.3390\/jof4030079","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]}}}